Clinical Trials and Behavioral Studies

Our current active protocols are listed below. If you have any questions about the particular study protocol, please contact the study coordinator.  For more information about the research or participation in general, please call our office at 312-695-8643.

Feinberg Clinical Trials

Scientists at the medical school are conducting hundreds of clinical trials daily. Learn more about all our work via the Feinberg Office of Research Clinical Trials page. Search for trials by disease or condition.

CoordinatorPIStudy Description
Marko Mihailovic MAO, LCPC, CCRC
marko.mihailovic( at )northwestern.edu
312-503-9096
Morris Goldman, MD

Study Title: Oxytocin Faces

Target Population: Adults 18 to 65 years old with psychosis.

Aim: To determine whether the hormone oxtyocin influences how patients interpret pictures of people’s faces.

Melody Fairchild, MAT
m-fairchild( at )northwestern.edu
312-503-7071
James Reilly, PhD

Study Title: Chicago Adolescent Longitudinal Study;

Target Population: Adolescents and young adults (ages 12 to 26 years old) with changes in thoughts, feelings, and behavior OR drug use.

Aim: To understand more about early phases of mental illness.

Krina Adhikari
krina.adhikari( at )northwestern.edu
312-503-9095
Evan Goulding, MD, PhD

Study Title: Mobile Monitoring for Long-Term Behavioral Data Collection in Bipolar Disorder

Target Population: Adults 18 to 65 years old with Bipolar Disorder.

Aim:  To evaluate the use of mobile phones for collecting behavioral data to improve the ability to detect symptoms and improve treatment.

To learn more about this study, please visit our website at http://livewell.northwestern.edu/.

Jessica Berger, LCSW
jessica.berger1( at )northwestern.edu
312-503-4995
Lei Wang, PhD

Study Title: HippoPCI

Target Population: Female breast cancer patients between 50 to 65 years old.

Aim: To improve our understanding of differences in size, shape and activity of a variety of brain areas that can occur in women with breast cancer undergoing adjuvant chemotherapy or hormonal therapy, and how these brain areas are related to the development of mild cognitive impairment as a result  treatment.

Melody Fairchild MAT
m-fairchild( at )northwestern.edu
312-503-7071
Mehmet E. Dokucu, MD PhD

Study Title: Repetitive Transcranial Magnetic Stimulation (rTMS) in Cancer Patients with Depression and Anxiety

Target Population: Cancer Patients between 22 to 70 years old who are currently depressed.

Aim: To test the safety and tolerability of left- and right-sided rTMS as a treatment for depression and anxiety in cancer survivors. 

Stephanie Schuette
nwu-sas375( at )northwestern.edu
1-855-99-ASHER
Crystal Clark, MD, MSc

Study Title: Pharmacokinetics of Lamotrigine in Pregnant and Postpartum Women with Bipolar Disorder

Target Population: Pregnant Women ages 18-45 years old who are taking daily Lamotrigine (Lamictal) for Bipolar Disorder.

Aim: To assess the impact of the dynamic physiology of pregnancy on the L/D ratio and bioavailability of LTG in women with Bipolar Disorder.

Sarah O'Dor, MS
northwesternresearchgroup( at )northwesten.edu
312-503-1802
Hans Breiter, MD

Study Title: Neurological Mechanisms of Treatment project (NMT)

Target Population: 14-16 year old adolescents either with a current Major Depressive Disorder diagnosis, or with no lifetime history of psychiatric illness

Aim: To examine how Cognitive Behavioral Therapy (CBT) changes brain activation in adolescents with Major Depressive Disorder.

Cale Wardell, BS
cale.wardell( at )northwestern.edu
312-503-9076
Herbert Meltzer, MD

Study Title: Auspex ARM-TD

Target Population: Adults 18 to 75 years old with diagnosis of Tardive Dyskinesia made at least 6 months prior to screening.

Aim: To reduce movements in Tardive Dyskinesia.

Cale Wardell, BS
cale.wardell( at )northwestern.edu
312-503-9076
Herbert Meltzer, MD

STUDY TITLE:  Effect of Magnesium Threonate (MgT) on Cognitive Enhancement in Schizophrenia 

Target Population: Adults 18-55 years of age inclusive

Aim: Determine if Magnesium Threonare (MgT) improves mental function and is safe in people who have schizophrenia

Anna Veluz-Wilkins, MA
a-veluz-wilkins( at )northwestern.edu
312-503-3098
Brian Hitsman, PhD

Study title:  Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers

Target population:  Adults aged 18-65 who smoke cigarettes daily, have a current or recent (past two years) diagnosis of major depressive disorder, and exhibit at least a mild level of depressive symptoms.

Aim:  The goal of double-blind, placebo-controlled, randomized controlled trial is to evaluate the efficacy and safety of behavioral activation plus varenicline for treating nicotine dependence in smokers with current or recent (past two years) major depressive disorder.

Anna Veluz-Wilkins, MA
a-veluz-wilkins( at )northwestern.edu
312-503-3098
Brian Hitsman, PhD

Study title: Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

Target population: Adults 18 years of age or older who smoke cigarettes weekly and have had a cancer diagnosis within the past 5 years.

Aim: Using a double-blind, placebo-controlled, randomized design, this study aims to compare standard varenicline treatment (12 weeks) to extended varenicline treatment (24 weeks) for increasing long-term smoking cessation in cancer patients.

Cale Wardell, BS
cale.wardell( at )northwestern.edu
312-503-9076
Herbert Meltzer, MD

Titile: Testing the ability of JNJ-18038683, a selective serotonin (5-HT)7 antagonist, to improve cognition and reduce residual depressive symptoms in stable bipolar depressed patients

Target Population: 18-60

Aim: To improve cognitive function in people with Bipolar Disorder

Germaine Gagni, MA
germaine.gagni( at )northwestern.edu
312- 503-9092
Jeffrey Rado, MD, MPH

Titile: A Cluster Randomized, Multi-center, Parallel-group, Rater-blind Study Comparing Treatment With Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia

Target Population: Individuals with schizophrenia from 18 to 35 years old

Aim:  To compare a Long-acting Injectable Antipsychotic (Aripiprazole) vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics (PRELAPSE)

Rebecca Newmark, BA
rebecca.newmark( at )northwestern.edu
312-695-6010 or 1-855-99-ASHER
Suena Massey, MD

Study Title: Cognitive and Affective Substrates of Smoking: Targets for Maternal Behavior Change

Target Population: Pregnant women who smoke cigarettes or recently quit smoking

Aim: To understand how the experience of smoking may change during pregnancy